Logo image of APVO

APTEVO THERAPEUTICS INC (APVO) Stock Fundamental Analysis

NASDAQ:APVO - Nasdaq - US03835L4059 - Common Stock - Currency: USD

0.8619  -0.03 (-3.53%)

After market: 0.88 +0.02 (+2.1%)

Fundamental Rating

2

APVO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. The financial health of APVO is average, but there are quite some concerns on its profitability. APVO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APVO had negative earnings in the past year.
APVO had a negative operating cash flow in the past year.
In the past 5 years APVO reported 4 times negative net income.
APVO had a negative operating cash flow in each of the past 5 years.
APVO Yearly Net Income VS EBIT VS OCF VS FCFAPVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -167.24%, APVO is not doing good in the industry: 85.74% of the companies in the same industry are doing better.
The Return On Equity of APVO (-559.13%) is worse than 80.63% of its industry peers.
Industry RankSector Rank
ROA -167.24%
ROE -559.13%
ROIC N/A
ROA(3y)-32.3%
ROA(5y)-41.16%
ROE(3y)-812.67%
ROE(5y)-577.31%
ROIC(3y)N/A
ROIC(5y)N/A
APVO Yearly ROA, ROE, ROICAPVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for APVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APVO Yearly Profit, Operating, Gross MarginsAPVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

APVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APVO has been reduced compared to 1 year ago.
APVO has less shares outstanding than it did 5 years ago.
APVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APVO Yearly Shares OutstandingAPVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
APVO Yearly Total Debt VS Total AssetsAPVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -27.40, we must say that APVO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -27.40, APVO is not doing good in the industry: 89.08% of the companies in the same industry are doing better.
There is no outstanding debt for APVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.4
ROIC/WACCN/A
WACC6.68%
APVO Yearly LT Debt VS Equity VS FCFAPVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 1.77 indicates that APVO should not have too much problems paying its short term obligations.
The Current ratio of APVO (1.77) is worse than 78.35% of its industry peers.
A Quick Ratio of 1.77 indicates that APVO should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.77, APVO is doing worse than 77.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.77
APVO Yearly Current Assets VS Current LiabilitesAPVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

APVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -713.99%.
EPS 1Y (TTM)-713.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1237.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.93% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.95%
EPS Next 2Y40.43%
EPS Next 3Y25.59%
EPS Next 5Y14.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APVO Yearly Revenue VS EstimatesAPVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 20M 40M 60M
APVO Yearly EPS VS EstimatesAPVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20K -40K -60K -80K -100K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APVO. In the last year negative earnings were reported.
Also next year APVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APVO Price Earnings VS Forward Price EarningsAPVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APVO Per share dataAPVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300 -400 -500

4.3 Compensation for Growth

APVO's earnings are expected to grow with 25.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.43%
EPS Next 3Y25.59%

More info and screens

0

5. Dividend

5.1 Amount

APVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APTEVO THERAPEUTICS INC

NASDAQ:APVO (4/17/2025, 8:02:15 PM)

After market: 0.88 +0.02 (+2.1%)

0.8619

-0.03 (-3.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-14 2025-02-14/bmo
Earnings (Next)05-06 2025-05-06
Inst Owners3.33%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change0%
Market Cap2.78M
Analysts82.86
Price Target21.42 (2385.21%)
Short Float %4.11%
Short Ratio1.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.53%
Min EPS beat(2)24.06%
Max EPS beat(2)75%
EPS beat(4)4
Avg EPS beat(4)50.06%
Min EPS beat(4)24.06%
Max EPS beat(4)75%
EPS beat(8)7
Avg EPS beat(8)46.78%
EPS beat(12)10
Avg EPS beat(12)71.86%
EPS beat(16)11
Avg EPS beat(16)39.02%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-89.74%
PT rev (3m)-89.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3600%
EPS NY rev (1m)0%
EPS NY rev (3m)86.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-530.07
EYN/A
EPS(NY)-16.16
Fwd EYN/A
FCF(TTM)-7.55
FCFYN/A
OCF(TTM)-7.55
OCFYN/A
SpS0
BVpS1.39
TBVpS1.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -167.24%
ROE -559.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.3%
ROA(5y)-41.16%
ROE(3y)-812.67%
ROE(5y)-577.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.77
Quick Ratio 1.77
Altman-Z -27.4
F-Score4
WACC6.68%
ROIC/WACCN/A
Cap/Depr(3y)21.85%
Cap/Depr(5y)15.73%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-713.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1237.18%
EPS Next Y96.95%
EPS Next 2Y40.43%
EPS Next 3Y25.59%
EPS Next 5Y14.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.37%
OCF growth 3YN/A
OCF growth 5YN/A